and Good our thank for Cook, everyone, for Knife Noel, Swiss the morning, you, Chris us. introduction. is Army With and joining thank Counsel. me Well, General today our you also
able I who of the Dr. August to our Chief Schoen, join Officer, star the Jim Medical today. to Eric be and us of also Financial Kupiec, investor as known well will as the Chancellor Officer. think exchequer, As the as our not Chief call
at database every statistical The routine to process analysis the the RETHINK-ALZ all Visit This a is weeks takes accuracy cleanup our and is the is As before place ago. ongoing. in we you first Phase Last know, locked several purpose the III clinical trial, the information begins. of ensure announced of it Patient/Last is of trial. end that Database
see we all this is promising before optimistic end time We expect will before the ultimately our could lead that We for data too best-in-class us. remain top is treatment of announce warranted line will the exciting of see This Alzheimer's, we to misplaced long. year. a but whether the results or trial to that an for optimism
There by revealed at say We sharing the biostatisticians data about Panthera we us look and you. to are our our much isn't unblinded our forward really Corporation. trial with more data can to until
As Light a reminder, as the to total from biomarker provide NFL, the protein for subset RETHINK same approximately known patients Glial and patients our GFAP results we time involve study Chain, at expect cognition otherwise our as from tau. data plasma report as This biomarker XXX, fibrillary Neurofilament of acidic will XXX pTau and data. a Known
couple I things. to be a reassured you want of about
will scrutiny the before under, Given twice company and that our once expect results. measure report been you can this has we we cut
that to be our bad you, data especially good, careful We report best ambiguous. we our ability. Also, is the sure to or to whether is accurate will be of we what will report it
or Madrid. Cassava, week, team conference from Last of attended CTAD Trials us Clinical for Disease Alzheimer's in the a
is headed to I Dr. have our by impressed I you team, which First, by tell Kupiec. am how Cassava
have ] are program. aren't is himself surrounded having assembled he Alzheimer's a member highly you for All-Star of Pfizer's cloth. of If investigators led with [ the virtual and respected team team group III Jim and has his many aware, same a a professionals our of Jim Phase private years, from for research Neuroscience who the dedicated community, cut team
our believe in in had would be Alzheimer's drug but are chance better lives doctors is I real reasonable trials involved, Lilly's want because same lecanemab. participate considered discovery their the mechanism in and donanemab for something and trials program in Eisai's successful Alzheimer's, as the that ran of sure their they needed working. make of If III successful, that they their know The to These They decided be who the to on best make they many business. I it also example, for as there from with action, the of involved could drug a the the trials a of are These of who difference. made live no Phase the of Eli had investigators simufilam, based people the investigators a for the drug patients. in know doctors the anyone hypothesized they investigators operation own the many difference Many assessment our were to thing of they well their a studied. the to privilege meet that principal and sites. are in believe met than innovation
participating Additionally, and grateful involved team. I it his given am associated to when much of its in be trust they and have in to by they truly this team. said these our I'm chose so Jim I no. the because to the have been to doctors courageous have trials who demonstrate just opportunity proud believe with would really easier remarkable potential simufilam to be have
last a a that are witnessed want very few but of interesting We I lot to focus week, presentations at CTAD on. there
biomarker key Alzheimer's the and call, one You There's over disease. been developing We innovation Research or indicates in clinical fluid asymptomatic if now beta beta Kupiec biomarker positivity of years. or has cerebral calls extremely find symptoms at several PET of measured patient tests explosion plasma of ourselves high in in commercially beta amyloid high available a CSF clearly the a that last plasma with scans. spinal is by that revolution a with in believe amyloid biomarkers demonstrating last of may Alzheimer's. correlation spoke in Alzheimer's point that brain as an of of scientists amyloid Neuro where recall are what an presence at our hallmarks Jim risk the the is he the the disease.
companies predictive that showed the is as by assays that from of has given a CTAD probability Eli disease result of the developed over Lilly, a test Diagnostics. X CXN XX%. biomarker and such One values, presentation positive person positive Fujirebio data All reported
postmortem sure agree be it [ at you'll I analysis. a ] think
Why am I of respect way with to types the specifically change the patient power because these to practiced this bringing journey. medicine tools is Alzheimer's the up have
industry mentioned that developing consultant. production. planning by that some capabilities, recall that last told I the up significantly for success. of to map we've a been manufacturing our may you commercial about quarter beginning like thinking just share ramping things help I'd Cassava's with informed out. an and I to of ingredient including plan experienced the you our with we're being specifically You we are active were pharmaceutical Those activities expanding
and not our opportunity, do understand even to not. potential I'm up we prescribed, widely could of people disease-modifying. I'm have trying on not recently, and vision the to know had hint commercial I look very need few just that that not physicians with the still diagnose they trials how however, we're all going read not I'm to do forecasts. that, what know efforts you We Before will know tools focus the inhibitors We opportunity that about Cholinesterase and though could until are that are give out, on like.
We market Alzheimer's. we to treat to describing you be do how successful.
antibody-based the prescribing Lilly are Eli monoclonal from recently doctors and approved Some drugs Eisai.
physician Alzheimer's. diagnose capabilities, their The at primary date, disease-modifying drugs have Although had help have typically these few well-known to options these suspect their or is limitations. they hand own care first new demonstrated the to doctors To patients. have
delayed the diagnosis the stages In is moderate to diagnosis but of many initial fact, uncertainty. tells us from patients due XX% PCP, quite disease of research is patient factors, that until advanced diagnostic often, in including a get their a and
Some the feel patient treatment and constraints, Doctors diagnosis. options emotional a of so causing adequately struggle PCPs trained with distress, definitive especially don't time fear are limited. determine to stigma also when
inhibitors that PCP his oral envision world treat to monoclonal to have more We that day posed and twice a medication excellent option superior drugs. option challenges the new treatment in position or the with much PCP doesn't better an by safety her be that patient. a with is the does a profile, is If a would antibody-based come cholinesterase for
Now of by could can Reimagine readily have PCPs their the accelerate doctor which and vision, and for PCPs actually treatment is that making with high we diagnostic revolutionary is treat if effective. preparing this initiated at opportunity. realize diagnosis assay confidence the our [ treatment couple and and revert convenient, can and ] in number a a If can patients. drug point biomarker we a cost-effective available accurate safe we prescribe that then the moments can plasma diagnose
patients underdiagnosed. is What States. like? But with We look that that the does the We the X diagnosed of are disease Alzheimer's disease considered also know we patients approximately be the half know is United in diagnosed to market there Alzheimer's know mild. currently million
the treated with patients about us million prescription are in tells X.X that XX% only research U.S. but each Alzheimer's Our diagnosed the patients of year for Alzheimer's are disease. approved drug a
all I prescribed scenario be if trials PCP. which time diagnose treatment simufilam reality. planning it more take still become to simufilam by see. want III is should like kind a execution successful. even results you that is are successful, could biomarkers if approval simufilam's pTau our become patients. is are for Even that to like reimagine first-of-a-kind we we comfortable Alzheimer's a simufilam possibilities the partner, potentially before We using will may specialty-like than it to would understand disease-modifying a our prefer treatment would This the of brilliant disease take we on physicians their if shows Phase XXX
And shy lean away proven our we few are team them. challenge. this up for this, work about We have way situations. months if that from is past doesn't in the and challenging the through anything We
this to patients and transforming Our diagnosed loved disease deserve experience that [ the Star the ones. can moments ] the way North front lines the they on of is be with treated so their is
provide the of vision Well, update. all like motivates Eric Schoen that at you call to you the over indulging now to will for financial a thank I'd Eric? who turn Cassava. with us
